Hemostemix Inc.
HMTXF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.70 | 0.17 | 0.03 | -0.01 |
| FCF Yield | -14.56% | -4.41% | 4.57% | -19.61% |
| EV / EBITDA | -52.33 | -165.71 | -9.94 | -7.30 |
| Quality | ||||
| ROIC | -268.38% | 26.61% | 45.30% | 95.76% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 3.60 | 2.60 | -0.26 | 1.38 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -160.36% | -337.42% | 118.64% | -4,377.73% |
| Safety | ||||
| Net Debt / EBITDA | -5.38 | -31.06 | -3.33 | -2.29 |
| Interest Coverage | -9.09 | -2.79 | -6.23 | -10.48 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -23,734,646.02 | 0.00 | 0.00 |